Skip to content
MarketNewsAPI
Product Live news Screener Coverage Pricing
Docs Overview REST API WebSocket API MCP server
Resources Use cases Blog Changelog Status Compare Contact
Log in Get API key Dashboard
EURONEXTPARIS:STMPA$42.50-0.72(-1.65%)Europe stocks slip on AI concerns, escalating Iran tensions5:25:13 AM ETGS$891.00-7.72(-0.86%)CORRECTED-Goldman Sachs raises 2027 Europe gas price forecasts on MidEast supply, winter risks5:24:15 AM ETAAPL$325.59-13.00(-3.84%)What analysts are saying as Apple's stock falls after earnings report5:20:00 AM ETTSLA$401.92-1.94(-0.48%)Tesla's China-made EV sales rise 10.3% y/y in October5:19:11 AM ETMETA$610.01+3.47(+0.57%)An artist says Meta's bots overwhelmed her website and left her scrambling to protect her business5:19:01 AM ETMSFT$505.95-1.08(-0.21%)I'm an employment law attorney. Here are the 3 steps you should take if you're offered a buyout like Microsoft's.5:15:01 AM ETPG$162.04-1.52(-0.93%)Here's Exactly How Much $5,000 in Procter & Gamble Has Paid Out in Dividends Since 20205:15:00 AM ETNVDL$29.14+0.90(+3.19%)Nvidia: Trade The Fear With NVDL5:13:25 AM ETGOOG$278.75+0.75(+0.27%)Google Parent Alphabet Just Hit a Major Milestone, and It Has Nothing to Do With Its $482 Billion Single-Session Loss5:06:01 AM ETCRWD$245.00+3.22(+1.33%)CrowdStrike and Lovable Secure the Next Generation of AI-Built Applications5:01:02 AM ETCRWD$245.00+3.22(+1.33%)CrowdStrike and Lovable Secure the Next Generation of AI-Built Applications5:01:00 AM ETCRWD$245.00+3.22(+1.33%)EY Builds Its Frontier AI and Cyber Resilience Business on CrowdStrike, Commits to Training Cyber Workforce on the Falcon Platform5:00:04 AM ETAMZN$246.54+0.83(+0.34%)See inside Amazon's robot warehouse5:00:01 AM ETULCC$7.43+0.98(+15.19%)EY Builds Its Frontier AI and Cyber Resilience Business on CrowdStrike, Commits to Training Cyber Workforce on the Falcon Platform5:00:00 AM ETAAPL$325.59-13.00(-3.84%)Apple's shares remain attractive over the next 12 months, says Neuberger's Flax4:57:04 AM ETCRWD$245.00+3.22(+1.33%)CrowdStrike Announces New Native AI Security Innovations on AWS4:55:02 AM ETCRWD$245.00+3.22(+1.33%)CrowdStrike Announces New Native AI Security Innovations on AWS4:55:00 AM ETGOOG$278.75+0.75(+0.27%)Alphabet: Meta Wins In Ads, But Google's AI Cloud Is More Profitable4:54:50 AM ETSHEL$105.88+0.94(+0.90%)Transaction in Own Shares4:53:18 AM ETCBRS$97.00+0.70(+0.73%)Cerebras: Q3 Could Validate The 2027 Story4:53:11 AM ETSPCX$137.99+1.65(+1.21%)SpaceX Buying Boost Mobile Won't Unlock Wireless for Musk4:52:00 AM ETNVDA$205.20+3.00(+1.48%)Nvidia orders data center clients to reduce China exposure: FT4:50:05 AM ETRSP$220.52+0.56(+0.25%)Worried About an AI Bubble? This ETF Could Be the Smartest Buy Right Now4:44:00 AM ETGMAB$55.75+0.81(+1.47%)A little-known biotech's high-stakes cancer bet just paid off and its shares doubled4:35:47 AM ET

CERS · NASDAQ

Cerus Corporation

$2.19 -0.14 (-6.01%)

Company overview

Cerus Corporation operates as a biomedical products company that focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is a proprietary technology for controlling biological replication designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; the INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and the INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen-reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficie…

Sector
Healthcare
Industry
Medical - Devices
Exchange
NASDAQ
Market cap
$441M
Employees
614
Headquarters
Concord, CA
Website
cerus.com
CEO
William Greenman
Listed
January 31, 1997
P/E
-42.69
Dividend yield
0.00%

Company financials

Revenue
$223M
Gross profit
$121M
Operating income
-$17.7M
EBITDA
-$14.5M
Net income
-$9.6M
EPS
-$0.05
Total assets
$223M
Total debt
$97.4M
Gross margin
54.31%
Net margin
-4.29%
Earnings yield
-2.34%

Revenue segmentation

By product (FY 2025)
By region (FY 2025)

Showing FY 2025

Price chart

1.842.262.683.113.53
CERS 1D NASDAQ O2.32H2.43L2.30C2.33+0.05 (+2.19%)Vol1.72M

News

15-min delaySigned-out view is delayed 15 minutes. Log in on Pro for the live news desk.

Start 7-day free trial See live plans
Source
Date
Type
View
Ticker Type Headline Source Published
CERSCerus Corporation Stock news Cerus Corporation (CERS) Q3 2026 Earnings Call Transcript Seeking Alpha
CERSCerus Corporation Stock news Cerus Q3 Earnings Call Highlights MarketBeat
CERSCerus Corporation Stock news BRIEF-Cerus May Offer And Sell Up To $150 Million Of Securities From Time To Time - SEC Filing Reuters
CERSCerus Corporation Stock news Cerus' blood-safety system meets main goal in late-stage trial Reuters
CERSCerus Corporation Stock news Cerus Q3 adjusted EBITDA beats analyst estimates on higher IFC sales, platelet franchise strength Reuters
CERSCerus Corporation Stock news BRIEF-Cerus Q3 Gross Profit USD 30.3 Million Reuters
CERSCerus Corporation Press release Cerus Corporation Announces Third Quarter 2026 Financial Results Business Wire
CERSCerus Corporation Press release Cerus Corporation Announces Positive Topline Results from Phase 3 RedeS Trial of the INTERCEPT Blood System for Red Blood Cells Business Wire
CERSCerus Corporation Stock news Cerus Corporation to Release Third Quarter 2026 Financial Results on November 2, 2026 Business Wire
CERSCerus Corporation Press release Cerus Corporation Announces Workshop and Abstracts at the 2026 AABB Annual Meeting Business Wire
CERSCerus Corporation Stock news Cerus: This Blood-Safety Underdog Should Be Earning More Respect Seeking Alpha
CERSCerus Corporation Press release Cerus Corporation Announces Second Quarter 2026 Financial Results Business Wire
CERSCerus Corporation Stock news Amova Asset Management Americas Inc. Sells 193,353 Shares of Cerus Corporation $CERS Defense World
CERSCerus Corporation Press release Cerus Corporation to Release Second Quarter 2026 Financial Results on July 30, 2026 Business Wire
CERSCerus Corporation Press release Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress Business Wire
CERSCerus Corporation Press release Cerus Corporation Closes New Debt Facility of Up to $110 Million Business Wire
CERSCerus Corporation Stock news Is BrightSpring Health Services, Inc. (BTSG) Stock Outpacing Its Medical Peers This Year? Zacks Investment Research
CERSCerus Corporation Press release Bradley L. Radoff Announces Intent to Withhold Votes from Chair and CEO William Greenman and Director Ann Lucena Business Wire
CERSCerus Corporation Stock news Cerus Corporation: Strong Q1 Results Validate The Turnaround Thesis Seeking Alpha
CERSCerus Corporation Stock news Cerus Corporation (CERS) Q1 2026 Earnings Call Transcript Seeking Alpha
See more
FAQ

Questions about Cerus Corporation

What does Cerus Corporation do?
Cerus Corporation operates as a biomedical products company that focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System is a proprietary technology for controlling biological replication designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which are designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; the INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and the INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen-reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficie…
What is CERS's market cap?
Cerus Corporation (CERS) is a listed stock with a live quote. The latest market cap on this page is $441M.
Where is Cerus Corporation headquartered?
Cerus Corporation is headquartered in Concord, CA.
How do I get CERS news from the API?
Call GET /v1/news?tickers=CERS. Add type=news, type=press_release, or type=legal to take one feed. Pro keys search articles since 2020 in real time. Free keys are delayed 15 minutes and return the last year. Signed-out visitors and Free accounts see that same year on this page. Pro sees articles since 2020.
How far back does CERS news go?
Signed-out visitors and Free accounts see the last year of stock news, press releases, and legal notices for CERS, 15 minutes behind, and each headline links to the publisher. Pro, including the 7-day trial, sees articles since 2020 as headlines are ingested. A Free API key returns the last year. Pro keys search articles since 2020.
Is the CERS price on this page from the API?
The price and daily change update during the US session for every visitor. That quote is context on this page. It is not part of the news API. The chart is one candle per session from the start of 2020. 1W, 1M, and 1Y group those sessions.
Can I use the Pro plan commercially?
No. The Pro plan cannot be used for commercial work. A product you sell, work you do for a client, or redistribution of the feed needs a custom plan and a license. Email [email protected].

Real-time stock news for $15 a month.

Start a 7-day Pro trial. A card is required. REST, WebSocket, and MCP are included, with 1,000 REST requests a day. You won't be charged during the trial. Unless you cancel, the card is billed for Pro when it ends.

Start 7-day free trial Read the docs